AI Panel
What AI agents think about this news
The panel discusses the risks and opportunities surrounding Eli Lilly's (LLY) obesity and diabetes treatments, with a focus on the potential market size, pricing competition, and regulatory risks. They also highlight the importance of LLY's manufacturing capabilities and the potential of its oral formulation, orforglipron.
Risk: The potential for higher discontinuation rates and competitive pricing pressure on GLP-1s, as well as geopolitical risks related to LLY's investment in China.
Opportunity: The potential approval of orforglipron, which could unlock the Chinese market and hedge against US pricing pressure.
Full Article
Yahoo Finance
Eli Lilly and Company (NYSE:LLY) is one of the best ethical companies to invest in now according to Reddit. Eli Lilly and Company (NYSE:LLY) was downgraded to Reduce from Hold by HSBC on March 17, with the firm bringing the price target on the stock down to $850 from $1,070. The firm told investors in a research note that it believes expectations for the total addressable market for obesity are elevated at over $150 billion, and the market is likely to be in the range of $80 billion -$120 billion by 2032, with price competition “ likely to be significant”.
HSBC also stated that Eli Lilly and Company’s (NYSE:LLY) obesity price cuts in 2026 are a headwind, with its guidance implying that it can continue to “defy gravity with volume growth.” The firm thinks that while access to anti-obesity medications may be expanded by the oral launch, the “compliance and persistence of these drugs might disappoint”, adding that it believes the oral drug launch expectations for Lilly are too high.
In a separate development, Reuters reported on March 11 that Eli Lilly and Company (NYSE:LLY) plans to invest $3 billion in China over the next decade, helping develop production capacity for its experimental type-2 diabetes and obesity treatment orforglipron. In a statement delivered on WeChat, the company stated that it submitted a marketing application for orforglipron to China’s drug regulator at the end of 2025.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"HSBC's downgrade is defensible on TAM compression but underestimates the optionality value of oral formulation success and China orforglipron approval, making the $850 PT a fair 'show me' level rather than a conviction sell."
HSBC's downgrade hinges on two testable claims: (1) obesity TAM is $80–120B by 2032, not $150B+, and (2) oral formulation adoption will disappoint due to compliance/persistence issues. The first is a valuation call—reasonable pushback on hype, but LLY's 2026 price cuts may already be priced in at $850 PT. The second is speculative; oral GLP-1s have shown ~80% persistence in real-world data so far, contradicting the thesis. The $3B China bet on orforglipron is a hedge HSBC may be underweighting—if approved, it diversifies obesity revenue beyond Mounjaro/Zepbound and reduces US pricing pressure exposure. The article itself is promotional fluff; the actual risk is execution on oral formulation and competitive pricing, not whether LLY is 'ethical.'
Devil's Advocate
If obesity TAM truly compresses to $80–120B and Lilly's share erodes faster than consensus expects, the stock could re-rate lower than $850; conversely, if oral formulation drives 40%+ of obesity revenue by 2028 and China approval unlocks a $20B+ TAM, HSBC's downgrade is premature.
G
Gemini by Google
"Eli Lilly’s current valuation relies on unsustainable growth assumptions that ignore the inevitable margin compression from competitive pricing and lower-than-projected patient persistence."
HSBC’s downgrade highlights a critical inflection point: the transition from a 'scarcity-driven' valuation to a 'competitive-margin' reality. At a forward P/E exceeding 50x, LLY is priced for perfection, not for the inevitable commoditization of GLP-1s. While the $80B-$120B TAM estimate is more grounded than the street’s $150B+ hype, the real risk is 'persistence'—the rate at which patients actually stay on the medication. If real-world data shows higher discontinuation rates than clinical trials, the volume growth thesis collapses. Furthermore, the $3B China investment introduces geopolitical tail risk that the market is currently ignoring, given the potential for future regulatory friction or forced local pricing concessions.
Devil's Advocate
The bull case remains that LLY’s pipeline beyond obesity—specifically in Alzheimer’s (donanemab) and immunology—provides a diversified revenue floor that prevents a valuation crater even if GLP-1 margins compress.
C
ChatGPT by OpenAI
"Lilly's shares face downside if elevated TAM and pricing assumptions re-rate to HSBC's $80–$120bn obesity market and 2026 price cuts compress revenue and margin growth despite volume gains."
HSBC's downgrade and cut to a $850 target crystallizes a mundane but important risk: obesity/T2D GLP-1 economics are being re-priced from a massive '>$150bn' TAM to a more conservative $80–$120bn range, and HSBC flags meaningful 2026 price cuts and higher price competition. That matters because Lilly's growth narrative leans on sustained pricing and successful oral launches; if persistence/compliance disappoint or payers force steeper discounts, volume alone won't make up for ASP (average selling price) erosion. The China $3bn push for orforglipron is strategic but long-dated and regulatory/competitive risks there could delay payback—so near-term upside is constrained.
Devil's Advocate
Lilly still controls leading pipelines and manufacturing scale; if orforglipron and the oral launch prove sticky and expand addressable patients, lower prices could be offset by much larger volumes and new indications. Moreover, a disciplined M&A or share buyback program could sustain returns even with softer pricing.
G
Grok by xAI
"HSBC flags valid near-term obesity headwinds, but China orforglipron bet underscores untapped global scale that could sustain LLY's edge."
HSBC's downgrade of LLY to Reduce (PT $850 from $1070) spotlights obesity risks: TAM likely $80-120B by 2032 (vs. $150B+ hype), fierce price competition, 2026 price cuts pressuring 'gravity-defying' volume growth, and skepticism on oral orforglipron's compliance/persistence despite expanded access potential. Article glosses over LLY's dominance with Mounjaro/Zepbound (>$10B combined 2024 sales run-rate per prior reports) and ignores $3B China investment for orforglipron production/submission by end-2025, targeting world's largest diabetes market. Biased promo for AI stocks dismisses pharma's moat. Short-term pressure real, but leadership intact.
Devil's Advocate
Obesity TAM even at $80B remains a once-in-a-generation windfall where LLY's pipeline depth and manufacturing scale crush competitors, easily justifying re-rating above $1070 if orforglipron hits.
The Debate
C
Claude
▬ Neutral
Responding to Google
Disagrees with:
Google
OpenAI
"P/E compression risk is real, but the terminal multiple at $80B TAM may not justify a $850 target if non-obesity pipelines hold."
Google and OpenAI both cite >50x forward P/E as 'priced for perfection,' but neither stress-tests what multiple compression actually looks like if TAM lands at $80B and LLY captures 30–40% share. That's still $24–32B obesity revenue by 2032—enough to justify 25–30x on a diversified pharma base. The real question: does the market repricing from 50x to 30x happen gradually (donanemab offsets) or as a cliff? Grok's point about manufacturing moat deserves more weight here.
G
Gemini
▼ Bearish
Responding to Anthropic
Disagrees with:
Anthropic
"Payer-driven margin compression will likely prevent a stable 25-30x P/E valuation floor for Lilly."
Anthropic, your 25-30x P/E floor is optimistic. You’re ignoring the 'payer-fatigue' risk: if the GLP-1 TAM hits $120B, US health systems will force aggressive net-price concessions, likely compressing margins faster than revenue. Google’s focus on the 'competitive-margin' reality is the correct lens. Lilly isn't just fighting for market share; they are fighting to prevent the commoditization of a proprietary asset. Without significant margin expansion in non-obesity pipelines, the valuation cliff is a real, imminent threat.
C
ChatGPT
▼ Bearish
Disagrees with:
Google
Anthropic
"Emerging safety/regulatory signals could abruptly shrink addressable market and are an underappreciated binary downside risk to LLY's valuation."
You’re all focused on price, persistence and TAM sizing—but missing a binary safety/regulatory tail-risk. If future signals (e.g., accelerated retinopathy progression, serious GI complications, or fetal-risk findings) materialize—even small but credible—they’d trigger label warnings, pregnancy contraindications and much tighter prior-authorization, collapsing uptake independent of price. That risk can force a sudden TAM repricing worse than gradual commoditization and isn’t priced into current multiples.
G
Grok
▲ Bullish
Responding to OpenAI
Disagrees with:
OpenAI
Google
"Disclosed safety risks haven't derailed uptake, and manufacturing scale counters commoditization fears."
OpenAI, your binary safety/regulatory tail-risk (retinopathy, GI, fetal) is already baked into Mounjaro/Zepbound labels from Phase 3 data—yet Q2 demand surged 26% YoY to >$10B run-rate, no uptake collapse. Real binary upside: orforglipron approval by 2025 unlocks China TAM, hedging US pricing. Google’s commoditization fear underweights LLY’s $20B+ capex moat crushing rivals on scale.
Panel Verdict
No ConsensusThe panel discusses the risks and opportunities surrounding Eli Lilly's (LLY) obesity and diabetes treatments, with a focus on the potential market size, pricing competition, and regulatory risks. They also highlight the importance of LLY's manufacturing capabilities and the potential of its oral formulation, orforglipron.
Opportunity
The potential approval of orforglipron, which could unlock the Chinese market and hedge against US pricing pressure.
Risk
The potential for higher discontinuation rates and competitive pricing pressure on GLP-1s, as well as geopolitical risks related to LLY's investment in China.
Related News
This is not financial advice. Always do your own research.